Drug Trial Radar · NCT03972488
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
226
Actual
Start
Jan 8, 2020
Primary completion
Jul 20, 2023
Study completion Oct 29, 2027
Sponsor
- Lead sponsor
- Advanced Accelerator ApplicationsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients were eligible, as well as patients previously treated with SSAs in the absence of progression.
Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
LutatheraDrug
Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)Drug
Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½" 19-gauge needles, and two alcohol wipes.
2.5% Lys-Arg sterile amino acid solutionDrug
Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
High dose 60 mg octreotide long-acting repeatableDrug
Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½" 19-gauge needles, and two alcohol wipes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Per Central AssessmentTime frame: from randomization to the first line progression or death due to any cause, up to approx. 42 months
Locations
40 sites in 9 countries. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut
USF - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
University of Iowa Hospitals and Clinics - Oncology
Iowa City, Iowa
University of Kentucky UK Markey Cancer Center
Lexington, Kentucky
Mayo Clinic - Oncology
Rochester, Minnesota
MD Anderson Cancer Center
Houston, Texas
London Health Sciences Centre, University of Western Ontario - Oncology
London, Canada
Centre Hospitalier Universitaire de Quebec
Québec, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
BC Cancer Agency
Vancouver, Canada
CHU Paris Nord-Val de Seine
Clichy, France
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot
Lyon, France
Institut du Cancer de Montpellier - Oncology
Montpellier, France
CHU-Hôtel Dieu Service de Médecine Nucléaire
Nantes, France
Institut Gustave Roussy
Villejuif, France
Universitätsklinikum Erlangen
Erlangen, Germany
Universitätsklinikum Essen - Klinik für Nuklearmedizin
Essen, Germany
A.O.di Bologna Policl.S.Orsola
Bologna, Italy
University of Genova - Oncology
Genova, Italy
Istituto Oncologico Romagnolo
Meldola, Italy
Fondazione Irccs Istituto Nazionale Tumori
Milan, Italy
Ieo, Irccs
Milan, Italy
IRCCS fondazione Pascale - Oncology
Naples, Italy
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology
Reggio Emilia, Italy
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology
Roma, Italy
Erasmus Medisch Centrum
Rotterdam, Netherlands
UMC Utrecht - Oncology
Utrecht, Netherlands
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Asan Medical Center - Oncology
Seoul, South Korea
Seoul National University Hospital - Department of Internal Medicine
Seoul, South Korea
Severance Hospital, Yonsei University Health System - Medical Oncology
Seoul, South Korea
Hospital Universitario Vall d'Hebrón
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
Guys And St Thomas Hospital
London, United Kingdom
Kings College Hospital - Oncology
London, United Kingdom
Royal Free Hospital, London
London, United Kingdom
Weston Park Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.